Elevatus is thrilled to announce that it has raised $10,500,000 in its latest funding round, marking a pivotal moment in the company’s journey to redefine recruitment through artificial intelligence. As an end-to-end recruitment software solution, Elevatus leverages pioneering AI technologies to automate the entire talent management lifecycle—right from crafting job requisitions to seamlessly onboarding new hires. Since its inception in 2019, the company has empowered over 150 global organizations by streamlining core recruitment operations, enabling businesses to beat the talent hunt, secure paperless processes, and transform their tech stacks into unified recruiting powerhouses. This latest infusion of capital is a testament to the confidence that investors have in Elevatus’s innovative approach and its ability to integrate cutting-edge technology with advanced recruiting solutions. With strategic partnerships and world-class integrations with industry giants like Oracle, SAP, LinkedIn, Slack, Zoom, and Google Meet, among others, Elevatus is uniquely positioned to drive innovation further. The funds will be channelled into scaling up research and development efforts, expanding global market presence, and enhancing the platform’s capabilities to support an even more dynamic and agile recruitment environment. Additionally, Elevatus will continue to cultivate its impressive roster of partnerships and enterprise relationships, while investing in new features that anticipate the evolving recruitment needs of modern organizations. This significant financial boost not only reinforces Elevatus’s commitment to revolutionizing talent acquisition but also empowers its team of visionary professionals dedicated to pushing the boundaries of AI in recruitment—one solution at a time.
Elevatus Secures $10.5M Series A Funding to Revolutionize AI-Driven Recruitment Worldwide
Get the full Elevatus company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laverock Therapeutics
Next generation programmable cell therapies
$2.8M Grant
today
GNOSIS Health Limited
Gnosis Health is a digital health spinout from Newcastle University developing tools for Parkinson’s disease management. Its platform, MAXine, integrates a patient app, conversational AI, and wearables to enable real-time symptom tracking and personalised insights. The company targets the self-pay healthtech market through direct-to-consumer subscriptions, with additional revenues from pharma and providers. Gnosis has completed clinical trials, secured NHS pilot partnerships, is a certified medical device, holds a growing patent portfolio, and has Innovate UK funding and HMRC Advance Assurance. The company is now scaling to other chronic conditions and global markets, with early commercial traction and inbound demand.
$1.4M Seed
today
Board
Board’s Enterprise Planning Platform delivers solutions that help over 2,000 organizations worldwide plan smarter — enabling actionable insights and better outcomes. Board helps leading enterprises discover crucial insights which drive business decisions and unify strategy, finance and operations through more integrated and intelligent planning to achieve full control of performance. Partnering with Board, global enterprises such as H&M, BASF, Burberry, Toyota, Coca-Cola, Kraft Heinz, and HSBC have deployed end-to-end planning applications at a fraction of the time and cost associated with traditional solutions. Board International was founded in 1994 and now has 25 offices around the world and a global reseller network. Board has been implemented in over 100 countries. Board International has long been recognized by leading analysts and subject matter experts including Gartner, Nucleus, and Dresner. Headquartered in Switzerland and US, Board International has branches in Argentina, Australia, Benelux, Nordics, Germany, France, India, Italy, Japan, Mexico, Singapore, Spain, UAE and UK and a worldwide network of distributors and certified partners. Board International is an equal opportunity employer and is committed to a diverse and inclusive workforce.
$20.0M Series a
today
KOSMOS
When something breaks, your team spends hours investigating what happened across Jira, Salesforce, GitHub, and ServiceNow before they can fix anything. Kosmos connects those signals automatically, surfaces root cause in seconds, and reduces MTTR and repeat incidents. Every correlation is proposed by machine, confirmed by human, and learned by the system.
$5.0M Seed
today
NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale. All correspondence from NewLimit will come from an @NewLimit.com email address.
$435.0M Unknown
today
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Board United States | Series a | $20.0M | today |
| 2 |  Alitheon United States | Series a | $8.0M | today |
| 3 |  Tavo Biotherapeutics | Series a | $17.0M | today |
| 4 |  Adaptive Innovations Corp United States | Series a | $50.0M | today |
| 5 |  Novellia United States | Series a | $18.0M | today |